Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Ratios

Immuneering (IMRX) Other financing activities (2020 - 2024)

Immuneering has reported Other financing activities over the past 3 years, most recently at $40988.0 for Q4 2024.

Quarterly results put Other financing activities at $40988.0 for Q4 2024, changed N/A from a year ago — trailing twelve months through Dec 2024 was $127362.0 (down 54.74% YoY), and the annual figure for FY2025 was $3.7 million, up 8991.11%.
Other financing activities for Q4 2024 was $40988.0 at Immuneering, down from $86374.0 in the prior quarter.
Over the last five years, Other financing activities for IMRX hit a ceiling of $226775.0 in Q4 2022 and a floor of $40988.0 in Q4 2024.
Median Other financing activities over the past 3 years was $86374.0 (2024), compared with a mean of $124951.2.